National Institutes of Health Center for Human Immunology Conference, September 2009: Meeting the human immunology challenge

Annals of the New York Academy of Sciences

Volumn 1200, Issue SUPPL.1, 2010, Pages

  Nussenblatt, Robert B ^a   Bielekova, Bibiana ^b   Childs, Richard ^c   Krensky, Alan ^d   Strober, Warren ^e   Trinchieri, Giorgio ^d  

^a NATIONAL EYE INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Bench to bedside approaches; Immunobiology; Immunology

Indexed keywords

ANIMAL; ARTICLE; AUTOIMMUNE DISEASE; CHRONIC DISEASE; DISEASE MODEL; HUMAN; IMMUNOLOGY; INFECTION; INFLAMMATION; LEUKOCYTE COUNT; LYMPHOCYTE; LYMPHOCYTE COUNT; MOUSE; NEOPLASM; PATHOPHYSIOLOGY; SPECIES DIFFERENCE; STEM CELL TRANSPLANTATION;

ANIMALS; AUTOIMMUNE DISEASES; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; HUMANS; INFECTION; INFLAMMATION; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; LYMPHOCYTES; MICE; NEOPLASMS; SPECIES SPECIFICITY; STEM CELL TRANSPLANTATION;

EID: 84877690956     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05682.x     Document Type: Conference Paper

References (65)

1. Nussenblatt, R.B., F. Marincola & A. Schechter 2010. Translational medicine-doing it backwards. J. Transl. Med. 8: 12.
2. Krensky, A.M. et al 1983. The functional significance, distribution, and structure of LFA-1, LFA-2, and LFA-3: cell surface antigens associated with CTL-target interactions. J. Immunol. 131: 611-616.
3. Krensky, A.M. & C. Clayberger 2009. Biology and clinical relevance of granulysin. Tissue Antigens 73: 193-198.
4. Mestas, J. & C.C. Hughes 2004. Of mice and not men: differences between mouse and human immunology. J. Immunol. 172: 2731-2738.
5. Billiau, A. 1995. Interferons in multiple sclerosis: warnings from experiences. Neurology 45: S50-S53.
6. Bluestone, J.A. et al 2010. Ten years of the Immune Tolerance Network: an integrated clinical research organization. Sci. Transl. Med. 2: 19 cm7.
7. Bluestone, J.A., J.B. Matthews & A.M. Krensky 2000. The immune tolerance network: the "Holy Grail" comes to the clinic. J. Am. Soc. Nephrol. 11: 2141-2146.
8. Fauci, A.S. 2006. Emerging and re-emerging infectious diseases: influenza as a prototype of the host-pathogen balancing act. Cell 124: 665-670.
9. Johnston, M.I. & A.S. Fauci 2008. An HIV vaccine-challenges and prospects. N. Engl. J. Med. 359: 888-890.
10. Hall, B.F. & A.S. Fauci 2009. Malaria control, elimination, and eradication: the role of the evolving biomedical research agenda. J. Infect. Dis. 200: 1639-1643.
11. Libby, P., P.M. Ridker & G.K. Hansson for the Leducq Transatlantic Network on Atherothrombosis. Inflammation in Atherosclerosis. 2009. From Pathophysiology to Practice. J. Am. Coll. Cardiol. 54: 2129-2138.
12. Libby, P. 2009. Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis. J. Lipid Res. 50(Suppl): S352-S357.
13. Andersson J., P. Libby & G.K. Hansson 2010. Adaptive immunity and atherosclerosis. Clin. Immunol. 134: 33-46.
14. Rocha, V.Z. & P. Libby 2009. Obesity, inflammation, and atherosclerosis. Nat. Rev. Cardiol. advance online publication 28 April 2009.
15. Libby, P. & F. Crea F. 2010. Clinical implications of inflammation for cardiovascular primary prevention. Eur. Heart J. 31: 777-783.
16. Nussenblatt, R.B., B. Liu & Z. Li 2009.Age-related macular degeneration: an immunologically driven disease. Curr. Opin. Investig. Drugs 10: 434-442.
17. Nussenblatt, R.B. & F. Ferris III. 2007. Age-related macular degeneration and the immune response: implications for therapy. Am. J. Ophthalmol. 144: 618-626.
18. Miller, D.H., O.A. Khan, W.A. Sheremata, et al 2003. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348: 15-23.
19. MS-Lenercept. 1999. TNF neutralization in MS: results of a randomized, placebo-controlledmulticenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 53: 457-465.
20. Mohan, N., E.T. Edwards, T.R. Cupps, et al 2001. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 44: 2862-2869.
21. Willerford, D.M., J. Chen, J.A. Ferry, et al 1995. Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity 3: 521-530.
22. Sharfe, N., H.K. Dadi, M. Shahar & C.M. Roifman 1997. Human immune disorder arising from mutation of the alpha chain of the interleukin-2 receptor. Proc. Natl. Acad. Sci. USA 94: 3168-3171.
23. + regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. 201: 723-735.
24. Engelhardt, B., T. Diamantstein & H. Wekerle 1989. Immunotherapy of experimental autoimmune encephalomyelitis (EAE): differential effect of anti-IL-2 receptor antibody therapy on actively induced and T-line mediated EAE of the Lewis rat. J. Autoimmun. 2: 61-73.
25. Nussenblatt, R.B., E. Fortin, R. Schiffman, et al 1999. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc. Natl. Acad. Sci. USA 96: 7462-7466.
26. Bielekova, B., N. Richert, T. Howard, et al 2004. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon {beta}. Proc. Natl. Acad. Sci. USA 101: 8705-8708.
27. Rose, J.W., H.E. Watt, A.T. White & N.G. Carlson 2004. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann. Neurol. 56: 864-867.
28. Oh, U., G. Blevins, C. Griffith, et al 2009. Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. Arch. Neurol. 66: 471-479.
29. Bielekova, B., M. Catalfamo, S. Reichert-Scrivner, et al 2006. Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2R{alpha}-targeted therapy (daclizumab) in multiple sclerosis. Proc. Natl. Acad. Sci. USA 103: 5941-5946.
30. Bielekova, B., T. Howard, A.N. Packer, et al 2009. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch. Neurol. 66: 483-489.
31. Howell, M.D., S.T. Winters, T. Olee, et al 1989. Vaccination against experimental allergic autoimmune encephalomyelitis with T cell receptor peptides. Science 246: 668-670.
32. Bielekova, B. & R. Martin 2001. Antigen-specific immunomodulation via altered peptide ligands. J. Mol. Med. 79: 552-565.
33. Bielekova, B., B. Goodwin, N. Richert, et al 2000. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 6: 1167-1175.
34. Comabella, M., J.D. Lunemann, J. Rio, et al 2009. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain 132: 3353-3365.
35. Kaser, A., S. Zeissig & R.S. Blumberg 2010. Inflammatory bowel disease. Annu. Rev. Immunol. 28: 573-621.
36. Strober, W. 2009. The multifaceted influence of the mucosal microflora on mucosal dendritic cell responses. Immunity 31: 377-388.
37. The National Commission on Digestive Disease Report http://www2.niddk.nih.gov/AboutNIDDK/CommitteesAndWorkingGroups/NCDD/FinalResearchPlanPosting.htm.
38. Karvonen, M., J. Pitkaniemi & J. Tuomilehto 1999. The onset age of type 1 diabetes in Finnish children has become younger. The Finnish Childhood Diabetes Registry Group. Diabetes Care 22: 1066-1070.
39. Ziegler, A.G., M. Hummel, M. Schenker & E. Bonifacio 1999. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes 48: 460-468.
40. Hummel, M., E. Bonifacio, S. Schmid, et al 2004. Brief communication: early appearance of islet autoantibodies predicts childhood type 1 diabetes in offspring of diabetic parents. Ann. Intern. Med. 140: 882-886.
41. Willcox, A., S.J. Richardson, A.J. Bone, et al 2009. Analysis of islet inflammation in human type 1 diabetes. Clin. Exp. Immunol 155: 173-181.
42. Herold, K.C., W. Hagopian, J.A. Auger, et al 2002. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346: 1692-1698.
43. Pescovitz, M.D., C.J. Greenbaum, H. Krause-Steinrauf, et al 2009. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N. Engl. J. Med. 361: 2143-2152.
44. Mastrandrea, L., J. Yu, T. Behrens, et al 2009. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care 32: 1244-1249.
45. Ludvigsson, J., M. Faresjo, M. Hjorth, et al 2008. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N. Engl. J. Med. 359: 1909-1920.
46. Dudley M.E., J.R. Wunderlich, P.F. Robbins, et al 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854.
47. Johnson, L.A., R.A. Morgan, M.E. Dudley, et al 2009. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114: 535-546.
48. Dudley, M.E., J.C. Yang, R. Sherry, et al Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26: 5233-5239.
49. Rosenberg, S.A. & M.E. Dudley 2009. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr. Opin. Immunol 21: 1-8.
50. Pascual, V., D. Chaussabel & J. Banchereau 2010. A genomic approach to human autoimmune diseases. Annu. Rev. Immunol. 28: 535-571.
51. Chaussabel, D., H. Ueno, J. Banchereau & C. Quinn 2009. Data management: it starts at the bench. Nat. Immunol. 10: 1225-1227.
52. Chaussabel, D., C. Quinn, J. Shen, et al 2008. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 29: 150-164.
53. Pascual, V., F. Allantaz, E. Arce, et al 2005. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 201: 1479-1486.
54. Bennett, L., A.K. Palucka, E. Arce, et al 2003. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197: 711-723.
55. Davis, M.M. 2008. A prescription for human immunology. Immunity 29: 835-838.
56. Rapoport, A.P., E.A. Stadtmauer, N. Aqui, et al 2005. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat. Med. 11: 1230-1237.
57. Leine, B.L., L.M. Humeau, J. Boyer, et al 2006. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc. Natl. Acad. Sci. USA 103: 17372-17377.
58. June, C.H., B.R. Blazar & J.L. Riley 2009. Engineering lymphocyte subsets: tools, trials and tribulations. Nat. Rev. Immunol. 9: 704-716.
59. Varela-Rohena, A., P.E. Molloy, S.M. Dunn, et al 2008. Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat. Med. 14: 1390-1395.
60. (+) T cells by genome editing using zinc-finger nucleases. Nat. Biotechnol 26: 808-816.
61. Takahashi Y, N Harashima, S Kajigaya, et al 2008. Regression of Kidney Cancer Following Allogeneic Stem-cell Transplantation Associated with T-Cells Recognizing a HERV-E Antigen. J. Clin. Invest. 118: 1099-1109.
62. Temple, R. 1994. Special study designs: early escape, enrichment, studies in non-responders. Communications in Statistics. 23: 499-531. (2) ICH E10. Choice of control group and related issues in clinical trials. FDA guidance document, issued May 2001 http://www.fda.gov/RegulatoryInformation/Guidances/ucm129459.htm accessed April 26, 2010.
63. Lovell, D.J., E.H. Giannini, A. Reiff, et al 2000. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N. Engl. J. Med. 342: 763-769.
64. Feldman, B., E., Wang, A. Willan, & J.P. Szalai 2001. The randomized placebo-phase design for clinical trials. J. Clin. Epidemiol. 54: 550-557.
65. Honkanen, V.E., A.F. Siegel, J.P. Szalai, et al 2001. A three-stage clinical trial design for rare disorders. Stat. Med. 20: 3009-3021.